Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tetrabenazine, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; maize starch; lactose monohydrate; magnesium stearate - may be useful for the control of chorea, hemiballismus, tardive and buccolingual dyskinesias and certain dystonic syndromes.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tretinoin, quantity: 0.5 mg/g - cream - excipient ingredients: cetyl alcohol; isopropyl palmitate; self-emulsifying glyceryl monostearate; sorbitan monostearate; polysorbate 60; dl-alpha-tocopheryl acetate; disodium edetate; propylene glycol; diazolidinyl urea; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water; retinol palmitate - retrieve is indicated for the adjunctive treatment of dry photoaged skin and related conditions.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - atropine sulfate monohydrate, quantity: 25 microgram; diphenoxylate hydrochloride, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: acacia; magnesium stearate; sucrose; sorbitol solution (70 per cent) (non-crystallising); light liquid paraffin; purified talc - lofenoxal is indicated as an adjunctive therapy for acute and chronic diarrhoea.tga approved 13 february 1985 date of last amendment 7 august 2007

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - pyridostigmine bromide, quantity: 60 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; acacia; magnesium stearate; maize starch; povidone; liquid paraffin; purified talc; rice starch; hard paraffin; iron oxide red; sucrose; pregelatinised potato starch - indications as at 3 august 1992: mestinon is useful in the treatment of myasthenia gravis.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propyl hydroxybenzoate; polysorbate 60; white soft paraffin; purified water; propylene glycol; stearyl alcohol - indications as at 30 july 1990: solar and senile keratoses, bowen's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - pyridostigmine bromide, quantity: 180 mg - tablet, modified release - excipient ingredients: zein; carnauba wax; colloidal anhydrous silica; magnesium stearate; calcium phosphate - indications as at 3 august 1992: mestinon is useful in the treatment of myasthenia gravis.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - pyridostigmine bromide, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; purified talc; lactose monohydrate; colloidal anhydrous silica; pregelatinised potato starch - indications as at 3 august 1992: mestinon is useful in the treatment of myasthenia gravis.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flucytosine, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; trometamol; water for injections - indications as at 15 march 1996: antocil is indicated in the treatment of generalised candidiasis, cryptococcosis and chromoblastomycosis.